Safe Emergency Department DIscharGE Rate (SEIGE)

Completed

• Conditions: Acute Coronary Syndrome; Acute Myocardial Infarction
• Interventions: Diagnostic Test: Cardiac Troponin Testing

• Registration Number: NCT04772157
• Lead Sponsor: Hennepin Healthcare Research Institute

Brief Summary

The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory.

The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).

Detailed Description

Study purpose/objective:

* Evaluate the clinical performance of the Siemens POC HS cTn-I test system for the diagnosis and rule out of AMI in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

* Correlate the blood and plasma outcomes on the Siemens POC HS cTn-I test system as function of the corresponding hematocrit (Hct) values.

Hypothesis: The Siemens POC HS cTn-I Test System will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.

Study Timeline

• Study Start: 2020-10-13
• Study First Submitted: 2021-02-23
• Study First Submitted QC: 2021-02-23
• Study First Posted: 2021-02-26
• Primary Completion: 2021-10-13
• Status Verified: 2024-10
• Study Completion: 2024-10-13
• Last Update Submitted: 2024-12-16
• Last Update Posted: 2025-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Presents to the ED, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible ACS event.
2. Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the first measurement.
3. At least one 12-lead electrocardiogram

Exclusion Criteria

1. Less than 21 years old
2. Pregnancy
3. Trauma
4. Declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes
5. Did not present through the ED
6. Transferred from an outside hospital or clinic.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cohort	Cardiac Troponin Testing	Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.

Primary Outcome Measures

Name	Time	Method
Examine the diagnostic performance for acute myocardial injury and acute myocardial infarction	Day 1	Examine the diagnostic performance for a) acute myocardial injury and b) acute myocardial infarction based on various diagnostic strategies using hs-cTnI measurement(s), as follows: 1. Single measurement strategies; 1. Limit of detection (LoD); 2. Concentration threshold tailored to meet a clinical need: Derive an optimal rule-out ng/L cutoff for Siemens POC HS cTn-I Test System.; 2. Accelerated serial sampling (0/2h protocol); 1. Using the both sex-specific and overall 99th percentiles; 2. Delta (absolute concentration serial change value, 0-2h) analysis
Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs	Day 1	Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs, including patients categorized with acute myocardial injury and acute myocardial infarction, including type 1 and 2 myocardial infarction following the 4th Universal Definition of Myocardial Infarction.
Impact on the incidence of myocardial injury and myocardial infarction diagnoses.	Day 1	Examine the potential impact on the incidence of myocardial injury and myocardial infarction diagnoses using hs-cTnI upon clinical practice implementation with a comparison to the hospital's final ICD-10 code diagnosis of type 1 and type 2 MIs.
Examine Concordance	Day 1	Examine concordance (dis) between hs-cTnI in comparison to a high sensitivity (Abbott \& Siemens Healthineers) cTnI assay
Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System	Day 1	Examine the incidence of undetectable(\<LoD), measurable (LoD - 99th percentile), and increased (\>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott \& Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles.

Secondary Outcome Measures

Name	Time	Method
Adjudicated index acute myocardial infarction according to 4th UDMI	on admission	acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction
Safety Outcome - MACE	30 days	Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure
All-cause mortality	up to 30 days	any death
Cardiac mortality	up to 30 days	death due to cardiac reasons

Trial Locations

Locations (1)

Hennepin Healthcare Research Institute / Hennepin County Medical Center; 🇺🇸 Minneapolis, Minnesota, United States